88 research outputs found
Robotic Surgery Versus Abdominal and Laparoscopic Radical Hysterectomy in Cervical Cancer
No full textNon
Cardiovascular Safety of Anti-TNF and Non-TNF Biological Therapy in Patients with Rheumatoid Arthritis
No full textPredictive Value of Cellular Immune Response and Tumor Biomarkers in Patients Surgically Treated for Cervical Cancer in Relation to Clinical Outcomes"
No full textNon
A role for b-cell-depleting agents in treating psoriatic skin lesions induced by tumor necrosis factor-alpha antagonists: A case report and literature review
No full textDespite recent advances in understanding the pathological pathways, clinical
pattern and management opportunities for new-onset psoriasis as a
paradoxical adverse event in patients receiving TNF inhibitors for their
immune-mediated disorder, there is a subset of patients who are either
partial responders or non-responders, whatever the therapeutic scenario. We
present the case of new-onset psoriasis and severe alopecia development in a
case study of long-standing rheumatoid arthritis (RA) treated with
adalimumab (ADA) and leflunomide. Since skin lesions and alopecia are
resistant to the classic protocol (topical treatment, ADA discontinuation)
and RA becomes highly active, rituximab (RTX) was started. Dramatic
improvement in joint disease, total remission of alopecia and partial
remission of pustular psoriasis were described after the first RTX cycle.
Although B-cell-depleting agents result in controversial effects on
psoriatic skin lesions, this is the first case of ADA-induced psoriasis and
alopecia that improved under RTX, suggesting a possible role in treating
such a patient population
5 Aminoacyl-tRNA Synthetases in Idiopathic Inflammatory Myopathies: An Update on Immunopathogenic Significance, Clinical and Therapeutic Implications
No full textAminoacyl-tRNA Synthetases in Idiopathic Inflammatory Myopathies: An Update on Immunopathogenic Significance, Clinical and Therapeutic Implications
No full textNon
FRI0076 THE RISK OF TUBERCULOSIS IN PATIENTS WITH IMMUNE-MEDIATED RHEUMATIC DISORDERS RECEIVING BIOLOGICAL THERAPY: A 15-YEAR EXPERIENCE IN A ROMANIAN COHORT
No full text- …
